Julie O’Neal

2.6k total citations
48 papers, 1.6k citations indexed

About

Julie O’Neal is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Julie O’Neal has authored 48 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 27 papers in Molecular Biology and 15 papers in Hematology. Recurrent topics in Julie O’Neal's work include CAR-T cell therapy research (15 papers), Multiple Myeloma Research and Treatments (12 papers) and Cancer, Hypoxia, and Metabolism (10 papers). Julie O’Neal is often cited by papers focused on CAR-T cell therapy research (15 papers), Multiple Myeloma Research and Treatments (12 papers) and Cancer, Hypoxia, and Metabolism (10 papers). Julie O’Neal collaborates with scholars based in United States, United Kingdom and Thailand. Julie O’Neal's co-authors include Jason Chesney, Brian F. Clem, Michael H. Tomasson, Amy Clem, Yoannis Imbert-Fernandez, Sucheta Telang, Alden C. Klarer, Jennifer Cain, Friederike Kreisel and Daniel Kerr and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Julie O’Neal

47 papers receiving 1.5k citations

Peers

Countries citing papers authored by Julie O’Neal

Since Specialization

Citations

This map shows the geographic impact of Julie O’Neal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie O’Neal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie O’Neal more than expected).

Fields of papers citing papers by Julie O’Neal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie O’Neal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie O’Neal. The network helps show where Julie O’Neal may publish in the future.

Co-authorship network of co-authors of Julie O’Neal

This figure shows the co-authorship network connecting the top 25 collaborators of Julie O’Neal. A scholar is included among the top collaborators of Julie O’Neal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie O’Neal. Julie O’Neal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model 2025 ·Blood Advances ·(unknown), (unknown), (unknown), Julie L. Prior, Brad Manion, (unknown), (unknown), (unknown), Rui Tang, Mark A. Fiala, John F. DiPersio, Deborah V. Novack, Julie O’Neal, Mikhail Y. Berezin, Monica Shokeen	1
2	Traversing the bench to bedside journey for iNKT cell therapies 2024 ·Frontiers in Immunology ·Julie O’Neal, Melissa Mavers, Reyka G. Jayasinghe, John F. DiPersio	5
3	Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc 2023 ·Blood Advances ·Julie O’Neal, Matthew Cooper, Julie Ritchey, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Feng Gao, Byung Ha Lee, Donghoon Choi, Melissa M. Berrien-Elliott, Alice Y. Zhou, Todd A. Fehniger, (unknown), John F. DiPersio	20
4	An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies 2023 ·Blood ·Jingyu Xiang, Jessica M. Devenport, (unknown), Karl Staser, Michael P. Rettig, Miriam Kim, Julie O’Neal, Julie Ritchey, Feng Gao, Garrett R. Rettig, Rolf Turk, Alexandra A. Wolfarth, Byung Ha Lee, Matthew Cooper, John F. DiPersio	3
5	Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo 2023 ·Blood ·Julie O’Neal, Julie Ritchey, (unknown), (unknown), Ramzi Abboud, Michael P. Rettig, (unknown), Linda Eissenberg, John F. DiPersio	1
6	CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells 2022 ·Leukemia ·Julie O’Neal, Julie Ritchey, Matthew Cooper, (unknown), (unknown), (unknown), Michael P. Rettig, (unknown), Leah Gehrs, Ramzi Abboud, Julie L. Prior, (unknown), Reyka G. Jayasinghe, Li Ding, Armin Ghobadi, Ravi Vij, John F. DiPersio	34
7	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy 2021 ·Leukemia ·Kinan Alhallak, Jennifer Sun, (unknown), (unknown), Julie O’Neal, Barbara Muz, Justin King, Daniel Kohnen, Ravi Vij, Samuel Achilefu, John F. DiPersio, Abdel Kareem Azab	45
8	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival 2020 ·Clinical Cancer Research ·Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan, (unknown), Mark A. Fiala, Julie O’Neal, (unknown), Julie Ritchey, Michael P. Rettig, (unknown), Steven Fletcher, Ravi Vij, John F. DiPersio, Gregory M. Lanza	19
9	Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Anchal Ghai, Alexander Zheleznyak, (unknown), Julie O’Neal, Julie Ritchey, Michael P. Rettig, John F. DiPersio, Monica Shokeen, Samuel Achilefu	9
10	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Scott Goldsmith, Mark A. Fiala, Julie O’Neal, George P. Souroullas, (unknown), Ravi Vij, Mark A. Schroeder	10
11	In vivo efficacy of BCMA-iNKT-CAR is enhanced by NT-I7, a long-acting IL-7 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Julie O’Neal, Julie Ritchey, Matthew Cooper, (unknown), (unknown), Byung Ha Lee, (unknown), Donghoon Choi, John F. DiPersio	2
12	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 2018 ·Blood Cancer Journal ·Brian S. White, Irena Lanc, Julie O’Neal, (unknown), Robert S. Fulton, Heather K. Schmidt, Catrina C. Fronick, Edward A. Belter, Mark A. Fiala, Justin King, Greg Ahmann, Mary DeRome, Elaine R. Mardis, Ravi Vij, John F. DiPersio, Joan Levy, Daniel Auclair, Michael H. Tomasson	35
13	Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer 2016 ·Breast Cancer Research and Treatment ·Julie O’Neal, Amy Clem, Lindsey Reynolds, Susan Dougherty, Yoannis Imbert-Fernandez, Sucheta Telang, Jason Chesney, Brian F. Clem	80
14	Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types 2015 ·PLoS ONE ·Sarah R. Amend, William C. Wilson, Liang Chu, Lan Lu, Pengyuan Liu, Daniel Serie, Xinming Su, Yalin Xu, Dingyan Wang, Anthony O. Gramolini, Xiao‐Yan Wen, Julie O’Neal, Michelle A. Hurchla, Celine M. Vachon, Graham A. Colditz, Ravi Vij, Katherine N. Weilbaecher, Michael H. Tomasson	25
15	Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells 2015 ·Experimental Hematology ·Zhiwen He, Julie O’Neal, William C. Wilson, Nitin Mahajan, (unknown), Yinan Wang, Mack Y. Su, Lan Lu, James B. Skeath, Deepta Bhattacharya, Michael H. Tomasson	8
16	Clinical development of cancer therapeutics that target metabolism 2015 ·QJM ·Brian F. Clem, Julie O’Neal, Alden C. Klarer, S. Telang, Jason Chesney	26
17	Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism 2014 ·Cancer & Metabolism ·Alden C. Klarer, Julie O’Neal, Yoannis Imbert-Fernandez, Amy Clem, (unknown), (unknown), Brian F. Clem, Jason Chesney, Sucheta Telang	81
18	6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27 2014 ·Cell Death and Disease ·Abdullah Yalçın, Brian F. Clem, Yoannis Imbert-Fernandez, (unknown), (unknown), Julie O’Neal, Alden C. Klarer, Amy Clem, S. Telang, Jason Chesney	155
19	The Function of the Conserved Regulatory Element within the Second Intron of the Mammalian Csf1r Locus 2013 ·PLoS ONE ·Kristin A. Sauter, Mohamed Amine Bouhlel, Julie O’Neal, David P. Sester, Hiromi Tagoh, Richard M. Ingram, Clare Pridans, Constanze Bonifer, David Hume	21
20	OCP1, an F-box protein, co-localizes with OCP2/SKP1 in the cochlear epithelial gap junction region 2001 ·Hearing Research ·Michael T. Henzl, Julie O’Neal, Richard Killick, Isolde Thalmann, Ruediger Thalmann	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact